NovaBridge Biosciences (NBP) Research & Development (2019 - 2025)

NovaBridge Biosciences (NBP) has reported Research & Development for 6 consecutive years, with $55.7 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Research & Development rose 823.02% year-over-year to $55.7 million; the TTM figure through Dec 2025 stood at $62.9 million (up 747.84% YoY), while the FY2025 annual figure was $62.9 million, up 188.95% from the prior year.
• Research & Development advanced to $55.7 million in Q4 2025 per NBP's latest filing, from $11.3 million in the prior quarter.
• Across five years, Research & Development topped out at $55.7 million in Q4 2025 and bottomed at -$143.1 million in Q4 2022.
• Historically, Research & Development has averaged -$5.4 million across 4 years, with a median of -$3.8 million in 2023.
• Annual changes were most pronounced in 2024 — Research & Development tumbled 82.64% — and 2025, when it soared 823.02%.
• NovaBridge Biosciences' Research & Development stood at -$143.1 million in 2022, then soared by 124.27% to $34.7 million in 2023, then sank by 82.64% to $6.0 million in 2024, then jumped by 823.02% to $55.7 million in 2025.
• Business Quant data shows NBP's Research & Development at $55.7 million in Q4 2025, $11.3 million in Q3 2025, and -$3.3 million in Q2 2025.